司维拉姆对血液透析患者钙蛋白颗粒的影响:SCaRF随机对照试验
SCaRF开放标签随机对照试验纳入31例稳定维持性血液透析患者,比较司维拉姆(盐酸司维拉姆+碳酸司维拉姆)与碳酸钙治疗24周对钙蛋白颗粒的影响。结果显示司维拉姆组血清CPP-1水平较碳酸钙组降低70%,且主动脉脉搏波速度和白细胞介素-8水平亦降低。
要点
- 司维拉姆较碳酸钙显著降低血清CPP-1水平达70%。
- 司维拉姆组主动脉脉搏波速度和IL-8水平亦显著降低。
- 两组常规矿物质代谢指标保持稳定。
核心结论
- 与碳酸钙相比,司维拉姆治疗24周与较低的血清CPP-1水平、主动脉脉搏波速度及全身炎症水平相关。
研究设计与样本
- 开放标签随机对照试验,纳入31例稳定维持性血液透析患者,随机分配至盐酸司维拉姆组、碳酸司维拉姆组或碳酸钙组,治疗24周。
主要发现
- 司维拉姆组(盐酸司维拉姆+碳酸司维拉姆)较碳酸钙组血清CPP-1水平降低70%(95%CI -90%至-15%,P=0.02),CPP-2无显著差异。
- 亚组分析中,碳酸司维拉姆组CPP-1降低83.4%(95%CI -95.7%至-36.8%,P=0.01)。
- 司维拉姆组较碳酸钙组主动脉脉搏波速度降低2.0 m/s(95%CI -2.9至-1.1),白细胞介素-8降低57%(95%CI -73%至-30%),两者P=0.01。
- 所有治疗组常规矿物质代谢指标保持稳定。
临床怎么用
- 对于维持性血液透析患者,选用司维拉姆(尤其是碳酸司维拉姆)可能有助于降低CPP-1水平、改善血管僵硬度及炎症状态。
局限性
- 开放标签设计,样本量较小(31例),亚组分析结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non-calcium-based phosphate binder sevelamer on CPP levels in patients undergoing hemodialysis (HD). We hypothesized that treatment with sevelamer would achieve greater reductions in amorphous calcium phosphate-containing CPP (CPP-1) and hydroxyapatite-containing CPP (CPP-2) owing to reduced calcium loading and anti-inflammatory pleiotropic effects. METHODS: We conducted an open-label, randomized controlled trial (RCT) in which 31 stable prevalent HD patients were allocated to receive either sevelamer hydrochloride (SH), sevelamer carbonate (SC), or CC for 24 weeks. Dual primary endpoints were the between groups differences in serum CPP-1 and CPP-2 levels at 24 weeks in SH + SC-treated versus CC-treated patients. Effects on aortic pulse wave velocity (aPWV), inflammatory cytokines (interleukin-6 and -8), and effects across individual treatment arms were also assessed. RESULTS: Serum CPP-1, but not CPP-2, levels were lower in those randomly assigned to the sevelamer (SH + SC) group compared with the CC group at 24 weeks (-70%, 95% confidence interval [CI] -90% to -15%, P = 0.02). In subgroup analysis, this effect was confined to those receiving SC (-83.4%, 95% CI -95.7% to -36.8%, P = 0.01). aPWV and interleukin-8 levels were also lower in those who received sevelamer compared with CC at 24 weeks (-2.0 m/s, 95% CI -2.9 to -1.1; -57%, 95% CI -73% to -30%, respectively, both P = 0.01). Conventional markers of mineral metabolism remained stable across all treatment groups. DISCUSSION: Compared with treatment with CC, use of sevelamer for 24 weeks was associated with lower serum CPP-1 levels and a reduction in aPWV and systemic inflammation.
引用
- Smith ER, Pan FFM, Hewitson TD, et al. Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial. Kidney Int Rep. 2020. PMID: 32954068. doi:10.1016/j.ekir.2020.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。